{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T16:19:45Z","timestamp":1773159585327,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:00:00Z","timestamp":1687996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K19451"],"award-info":[{"award-number":["JP19K19451"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Center for Global Health and Medicine,Japan","award":["26-D-002"],"award-info":[{"award-number":["26-D-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We aimed to estimate the cumulative incidence of treatment-requiring diabetic retinopathy since clinical diagnosis of diabetes based on the course of diagnosis\u00a0in a retrospective cohort study using Japan\u2019s medical claims and health checkup data (JMDC Claims Database; 2009\u20132020). We included patients whose diabetes was first diagnosed at medical facilities (hospitals\/clinics). We grouped them by health checkup participation before diagnosis, health checkup results, and antidiabetic medication promptly after the diagnosis. The incidence of treatment-requiring diabetic retinopathy (laser photocoagulation, intraocular injection, or vitrectomy) was compared among the groups. Of 126,696 patients, those who started an antidiabetic medication promptly after diabetes diagnosis without a recent health checkup faced the highest risk of treatment-requiring diabetic retinopathy (1-\/5-year cumulative incidence: 3.1%\/6.0%). This increased risk was consistently observed across various analyses, including the Cox proportional hazard model, sensitivity analysis restricting to those with an eye examination, and sensitivity analysis using vitrectomy as the outcome. Among patients with HbA1c\u2009\u2265\u20096.5% at recent health checkups, those who promptly started an antidiabetic medication had a higher risk (1.4%\/3.8%) than those who did not (0.7%\/2.7%). Taking the information about the course of diabetes diagnosis is important to manage risk stratification for diabetic retinopathy appropriately.<\/jats:p>","DOI":"10.1038\/s41598-023-37551-w","type":"journal-article","created":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T10:02:24Z","timestamp":1688032944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Different incidences of diabetic retinopathy requiring treatment since diagnosis according to the course of diabetes diagnosis: a retrospective cohort study"],"prefix":"10.1038","volume":"13","author":[{"given":"Takehiro","family":"Sugiyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Yanagisawa-Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Ihana-Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Ohsugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohjiro","family":"Ueki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanako","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,29]]},"reference":[{"key":"37551_CR1","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 183, 109119. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119 (2022).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"37551_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jdiacomp.2017.11.009","volume":"32","author":"N Nanayakkara","year":"2018","unstructured":"Nanayakkara, N. et al. Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. J. Diabetes Complicat. 32, 279\u2013290. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.11.009 (2018).","journal-title":"J. Diabetes Complicat."},{"key":"37551_CR3","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jdiacomp.2016.12.016","volume":"31","author":"MI Constantino","year":"2017","unstructured":"Constantino, M. I. et al. Data collection on retinopathy as a public health tool: The Hubble telescope equivalent of looking back in time. J. Diabetes Complicat. 31, 721\u2013725. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.12.016 (2017).","journal-title":"J. Diabetes Complicat."},{"key":"37551_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/bjo.2010.196204","volume":"95","author":"JD Ellis","year":"2011","unstructured":"Ellis, J. D. et al. Clues to duration of undiagnosed disease from retinopathy and maculopathy at diagnosis in type 2 diabetes: A cross-sectional study. Br. J. Ophthalmol. 95, 1229\u20131233. https:\/\/doi.org\/10.1136\/bjo.2010.196204 (2011).","journal-title":"Br. J. Ophthalmol."},{"key":"37551_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0168-8227(01)00349-7","volume":"56","author":"DP Liu","year":"2002","unstructured":"Liu, D. P. et al. Retinopathy in a Chinese population with type 2 diabetes: Factors affecting the presence of this complication at diagnosis of diabetes. Diabetes Res. Clin. Pract. 56, 125\u2013131. https:\/\/doi.org\/10.1016\/S0168-8227(01)00349-7 (2002).","journal-title":"Diabetes Res. Clin. Pract."},{"key":"37551_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/jgf2.422","volume":"22","author":"K Nagai","year":"2021","unstructured":"Nagai, K. et al. Data resource profile: JMDC claims database sourced from health insurance societies. J. Gen. Fam. Med. 22, 118\u2013127. https:\/\/doi.org\/10.1002\/jgf2.422 (2021).","journal-title":"J. Gen. Fam. Med."},{"key":"37551_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan, H. et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am. J. Epidemiol. 173, 676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433 (2011).","journal-title":"Am. J. Epidemiol."},{"key":"37551_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-021-00566-7","author":"A Yanagisawa-Sugita","year":"2022","unstructured":"Yanagisawa-Sugita, A. et al. Incidence of interventions for diabetic retinopathy and serious lower-limb complications and its related factors in patients with type 2 diabetes using a real-world large claims database. Diabetol. Int. https:\/\/doi.org\/10.1007\/s13340-021-00566-7 (2022).","journal-title":"Diabetol. Int."},{"key":"37551_CR9","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.2337\/dc21-0228","volume":"44","author":"WS Gange","year":"2021","unstructured":"Gange, W. S. et al. Incidence of proliferative diabetic retinopathy and other neovascular sequelae at 5 years following diagnosis of type 2 diabetes. Diabetes Care 44, 2518\u20132526 (2021).","journal-title":"Diabetes Care"},{"key":"37551_CR10","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.2337\/diacare.26.9.2604","volume":"26","author":"AMW Spijkerman","year":"2003","unstructured":"Spijkerman, A. M. W. et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice. Diabetes Care 26, 2604\u20132608 (2003).","journal-title":"Diabetes Care"},{"key":"37551_CR11","volume-title":"Clinical Epidemiology: The Essentials","author":"GS Fletcher","year":"2019","unstructured":"Fletcher, G. S. Clinical Epidemiology: The Essentials (Lippincott Williams & Wilkins, 2019)."},{"key":"37551_CR12","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1007\/s00125-017-4299-y","volume":"60","author":"RK Simmons","year":"2017","unstructured":"Simmons, R. K., Griffin, S. J., Lauritzen, T. & Sandb\u00e6k, A. J. D. Effect of screening for type 2 diabetes on risk of cardiovascular disease and mortality: A controlled trial among 139,075 individuals diagnosed with diabetes in Denmark between 2001 and 2009. Diabetologia 60, 2192\u20132199. https:\/\/doi.org\/10.1007\/s00125-017-4299-y (2017).","journal-title":"Diabetologia"},{"key":"37551_CR13","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2337\/diacare.15.7.815","volume":"15","author":"MI Harris","year":"1992","unstructured":"Harris, M. I., Klein, R., Welborn, T. A. & Knuiman, M. W. Onset of NIDDM occurs at least 4\u20137 yr before clinical diagnosis. Diabetes Care 15, 815\u2013819. https:\/\/doi.org\/10.2337\/diacare.15.7.815 (1992).","journal-title":"Diabetes Care"},{"key":"37551_CR14","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.2337\/dc13-2101","volume":"37","author":"M Porta","year":"2014","unstructured":"Porta, M. et al. Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care 37, 1668\u20131674. https:\/\/doi.org\/10.2337\/dc13-2101 (2014).","journal-title":"Diabetes Care"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37551-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T10:08:44Z","timestamp":1688033324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-37551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,29]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["37551"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-37551-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,29]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tamiya received a collaborative research fund from JMDC Inc. Sugiyama received a salary from University of Tsukuba in FY2018 and FY2019 based on the fund. However, the present study was unrelated to the collaborative research project, and the authors paid for database use. JMDC Inc. was not involved in study design, analysis, interpretation of data, writing the report, or any restrictions regarding submitting the report for publication. In contrast, JMDC Inc. was involved in generic data collection (not specific to the present study purpose). Ohsugi received honoraria for lectures from Novartis Pharma K.K., Sanofi K.K., and Eli Lilly Japan K.K; clinical commissioned\/joint research grants from Japan Diabetes Society, Novo Nordisk Pharma Ltd, Nippon Boehringer Ingelheim Co., Ltd, MSD K.K., Kyowa Kirin Co., Ltd, Abbott Japan LLC, and Sanofi K.K., as well as scholarship grants from Sumitomo Dainippon Pharma Co., Ltd, Mitsubishi Tanabe Pharma Corporation and Novartis Pharma K.K. Ueki received honoraria for lectures from Sumitomo Dainippon Pharma Co., Ltd, MSD K.K., Kyowa Kirin Co., Daiichi Sankyo, Nippon Boehringer Ingelheim Co., Ltd, Takeda Pharmaceutical Co., Ltd, Novo Nordisk Pharma Ltd, Mitsubishi Tanabe, AstraZeneca, Ono, Sanofi K.K, and Astellas; clinical research grants from Novo Nordisk Pharma Ltd, Nippon Boehringer Ingelheim Co., Ltd, Takeda Pharmaceutical Co., Ltd, Astellas, Eli Lilly, MSD K.K., and Abbott Japan LLC. These grants and honoraria were not received for this study. The other authors (Yanagisawa-Sugita, Tanaka, Ihana-Sugiyama, Imai, and Kobayashi) declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10527"}}